Investor relations
Here you will find financial information about Prostatype Genomics AB, and you can subscribe to newsletters and reports.
Rights issue 2026
On 29 June 2026, Prostatype Genomics AB (“Prostatype Genomics” or the “Company”) announced that the Board of Directors had resolved to carry out an issue of units – shares and two series of warrants – of initially up to approximately SEK 47.4 million before transaction costs with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The Rights Issue is covered by pre-subscription commitments, bottom- and top-town underwriting undertakings totalling approximately SEK 43.2 million, corresponding to approximately 91.3 percent of the Rights Issue. The purpose of the Rights Issue is to finance the continued Medicare reimbursement approval process and commercialization activities in the United States and Europe.
Important information about Nasdaq Stockholm First North Growth Market
The Nasdaq First North Growth Market is an alternative marketplace operated by the various exchanges that are part of NASDAQ.
Issuers on Nasdaq First North Growth Market are regulated by the rules of the Nasdaq First North Growth Market and not by the legal requirements for trading on a regulated (main) market. The risk of investing in a company traded on Nasdaq First North Growth Market may therefore be higher than an investment in a company traded on a regulated market. All companies whose shares are admitted to trading on Nasdaq First North Growth Market have a Certified Adviser who monitors compliance with the rules. NASDAQ Stockholm approves the application for admission to trading on the Nasdaq First North.
